Expression of p53 in colorectal carcinoma: Correlation with clinicopathologic features

Archives of Iranian Medicine

Volumn 10, Issue 1, 2007, Pages 38-42

  Ghavam Nasiri, Mohammad Reza ^a   Rezaei, Ezzatollah ^a   Ghafarzadegan, Kamran ^a   Seilanian Toosi, Mehdi ^a   Malekifard, Hamideh ^a  

^a MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Colorectal carcinoma; Immunohistochemistry; P53 gene; Protein expression

Indexed keywords

DNA; MONOCLONAL ANTIBODY; PARAFFIN; PROTEIN P53;

ADULT; AGE; AGED; ARTICLE; CANCER STAGING; CARCINOGENESIS; CELL COUNT; CELL DIVISION; CHI SQUARE TEST; CLINICAL FEATURE; COLORECTAL CARCINOMA; COLORECTAL SURGERY; CONTROLLED STUDY; CORRELATION ANALYSIS; DNA DAMAGE; FEMALE; GENE FUNCTION; GENE MUTATION; GENE OVEREXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IRAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; PATHOPHYSIOLOGY; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; SEX DIFFERENCE; TUMOR LOCALIZATION; UNIVERSITY HOSPITAL;

ADULT; AGED; AGED, 80 AND OVER; COLORECTAL NEOPLASMS; DISEASE PROGRESSION; DNA, NEOPLASM; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, P53; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; RETROSPECTIVE STUDIES; TUMOR MARKERS, BIOLOGICAL;

EID: 33846681844     PISSN: 10292977     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Parkin DM, Pisani P, Ferlay J. Global cancer statistics. CA Cancer J Clin. 1999; 49: 33.
2. Vogelstein B, Fearon ER, Hamilton SR, Kern SE, Preisinger AC, Leppert M, et al. Genetic alterations during colorectal-tumor development. N Engl J Med. 1988; 319: 525-532.
3. Harris AL. Mutant p53 - the commonest genetic abnormality in human cancer. J Pathol. 1990; 162: 5-6.
4. Harris CC, Hollestein M. Clinical implications of the p53 tumor-suppressor gene. N Engl J Med. 1993; 329: 1318-1327.
5. Komarova EA, Chamakov PM, Gudkov AV. TP53 in cancer origin and treatment. In: Cowell JK ed. Molecular Genetic of Cancer. 2nd ed. Oxford: Bios; San Diego, CA: Distributed by Academic Press; 2001: 195-216.
6. Kressner U, Glimelius B, Bergstrom R, Pahlman L, Larsson A, Lindmark G. Increased serum p53 antibody levels indicate poor prognosis in patients with colorectal cancer. Br J Cancer. 1998; 77: 1848-1851.
7. Matsushita H, Matsumura Y, Moriya Y, Akasu T, Fujita S, Yamamoto S, et al. A new method for isolating colonocytes from naturally evacuated feces and its clinical application to colorectal cancer diagnosis. Gastroenterology. 2005; 129: 1918-1927.
8. Lane DP. Cancer. P53, guardian of the genome. Nature. 1992; 358: 15-16.
9. Elsaleh H, Powell B, McCaul K, Grieu F, Grant R, Joseph D, et al. P53 alteration and microsatellite instability have predictive value for survival benefit from chemotherapy in stage III colorectal carcinoma. Clin Cancer Res. 2001; 7: 1343-1349.
10. Nasierowska-Guttmejer A, Trzeciak L, Nowacki MP, Ostrowski J. P53 protein accumulation and p53 gene mutation in colorectal cancer. Pathol Oncol Res. 2000; 6: 275-279.
11. Stewart RL, Royds JA, Burton JL, Heatley MK, Wells M. Direct sequencing of the p53 gene shows absence of mutations in endometrioid endometrial adenocarcinomas expressing p53 protein. Histopathology. 1998; 33: 440-445.
12. Nenutil R, Smardova J, Pavlova. S, Hanzelkova Z, Muller P, Fabian P, et al. Discriminating functional and non-functional p53 in human tumors by p53 and MDM2 immunohistochemistry. J Pathol. 2005; 207: 251-259.
13. Erill N, Colomer A, Verdu M, Roman R, Condom E, Hannaoui N, et al. Genetic and immunophenotype analyses of TP53 in bladder cancer: TP53 alterations are associated with tumor progression. Diagn Mol Pathol. 2004; 13: 217-223.
14. Tsai YY, Cheng YW, Lee H, Tsai FJ, Tseng SH, Chang KC. P53 gene mutation spectrum and the relationship between gene mutation and protein levels in pterygium. Mol Vis. 2005; 11: 50-55.
15. Roa JC, Roa I, Melo A, Araya JC, Villaseca MA, Flores M, et al. P53 gene mutation in cancer of the colon and rectum. Rev Med Chil. 2000; 128: 996-1004.
16. Colomer A, Erill N, Verdu M, Roman R, Vidal A, Cordon-Cardo C, et al. Lack of p53 nuclear immunostaining is not indicative of absence of TP53 gene mutations in colorectal adenocarcinomas. Appl Immunohistochem Mol Morphol. 2003; 11: 130-137.
17. Kressner U, Inganas M, Byding S, Blikstad I, Pahlman L, Glimelius B, et al. Prognostic value of p53 genetic changes in colorectal cancer. J Clin Oncol. 1999; 17: 593-599.
18. Gatta G, Ciccolallo L, Capocaccia R, Coleman MP, Hakulinen T, Moller H, et al. Differences in colorectal cancer survival between European and US populations: the importance of sub-site and morphology. Eur J Cancer. 2003; 39: 2214-2222.
19. Lanza G Jr, Maestri I, Dubini A, Gafa R, Santini A, Ferretti S, et al. P53 expression in colorectal cancer: relation to tumor type, DNA ploidy pattern, and short-term survival. Am J Clin Pathol. 1996; 105: 604-612.
20. Song GA, Deng G, Bell I, Kakar S, Sleisenger MH, Kim YS. Mucinous carcinomas of the colorectum have distinct molecular genetic characteristics. Int J Oncol. 2005; 26: 745-750.
21. Gervaz; P, Bouzourene H, Cerottini JP, Chaubert P, Benhattar J, Secic M, et al. Dukes B colorectal cancer: distinct genetic categories and clinical outcome based on proximal or distal tumor location. Dis Colon Rectum. 2001; 44: 364-373.
22. Soong R, Powell B, Elsaleh H, Gnanasampanthan G, Smith DR, Goh HS, et al. Prognostic significance of TP53 gene mutation in 995 cases of colorectal carcinoma. Influence of tumor site, stage, adjuvant chemotherapy, and type of mutation. Eur J Cancer. 2000; 36: 2053-2057.
23. Garcia-Hirschfeld-Garcia J, Blanes-Berenguel A, Vicioso-Recio L, Marquez-Moreno A, Rubio-Garrido J, Matilla-Vicente A. Colon cancer: p53 expression and DNA ploidy. Their relation to proximal or distal tumor site [in English and Spanish]. Rev Esp Enferm Dig. 1999; 91: 481-488.
24. Nancy Y, Assad M D, Mona A. Prognostic value of Cyclin D1 and p53 protein in colorectal carcinoma. Cancer Institute. 2000; 12: 283-292.
25. Erhan Y, Korkut MA, Kara E. Value of P53 protein expression and its relationship with short-term prognosis in colorectal cancer. Ann Saudi Med. 2002; 22: 5-6.
26. Liang JT, Huang KC, Cheng YM, Hsu HC, Cheng AL, Hsu CH, et al. P53 overexpression predicts poor chemosensitivity to high-dose 5-fluorouracil plus leucovorin chemotherapy for stage IV colorcctal cancers after palliative bowel resection. Int J Cancer. 2002; 97: 451-457.
27. Adell G, Sun XF, Stal O, Klintenberg C, Sjodahl R, Nordenskjold B. P53 status: an indicator for the effect of preoperative radiotherapy of rectal cancer. Radiother Oncol. 1999; 51: 169-174.
28. Diez M, Medrano M, Muguerza JM, Ramos P, Hernandez P, Villeta R, et al. Influence of tumor localization on the prognostic value of p53 protein in colorectal adenocarcinomas. Anticancer Res. 2000; 20: 3907-3912.
29. Schwandner O, Schiedeck TH, Bruch HP, Duchrow M, Windhoevel U, Broll R. Apoptosis in rectal cancer: prognostic significance in comparison with clinical, histopathologic, and immunohistochemical variables. Dis Colon Rectum. 2000; 43: 1227-1236.
30. Tang R, Wang JY, Fan CW, Tsao KC, Chen HH, Wu CM, et al. P53 is an independent pre-treatment markers for long-term survival in stage II and III colorectal cancers: an analysis of interaction between genetic markers and fluorouracil-based adjuvant therapy. Cancer Lett. 2004; 210: 101-109.
31. Gallego MG, Acenero MJ, Ortega S, Delgado AA, Cantero JL. Prognostic influence of p53 nuclear overexpression in colorectal carcinoma. Dis Colon Rectum. 2000; 43: 971-975.
32. Munro AJ, Lain S, Lane DP. P53 abnormalities and outcomes in colorectal cancer: a systematic review. Br J Cancer. 2005; 92: 434-444.